

**Catalog Number:** CM04695**产品信息****Catalog Number:** CM04695**CAS号:** 1446502-11-9**分子式:** C<sub>19</sub>H<sub>17</sub>F<sub>6</sub>N<sub>7</sub>O**主要靶点:**

IDH

**主要通路:**


Metabolic Enzyme

**分子量:** 473.375**MDL NO:** MFCD29472245**Pubchem ID:** 89683805.0**溶解度:**

DMSO 94 mg/mL

Water Insoluble

Ethanol 93 mg/mL

**靶点**

Target	Activity
IDH2 (R140Q)	IC50=100nM
IDH2 (R172K)	IC50=400nM

**动物研究****剂量:**Mice: 5 mg/kg - 45 mg/kg<sup>[3]</sup> (p.o.)**给药途径:**

p.o.

**描述**

Somatic point mutations in the active site of isocitrate dehydrogenase (IDH) 1 and 2 are found in multiple tumors. Enasidenib is a potent and selective inhibitor of the mutant IDH2. It inhibits the production of oncometabolite (R)-2-hydroxyglutarate (2HG) by the IDH2<sup>R140Q</sup> homodimer, the IDH2<sup>R140Q/WT</sup> heterodimer, and the IDH2<sup>R172K/WT</sup> heterodimer with IC<sub>50</sub> values of 0.1, 0.03, and 0.01  $\mu$  M, respectively. Enasidenib also displayed time-dependent potency for inhibiting the canonical forward (oxidative) reaction in the IDH2<sup>WT</sup> homodimer with an IC<sub>50</sub> value of 1.8  $\mu$  M. Moreover, Enasidenib inhibited 2HG production in HCT-116 K1 (IDH2<sup>R172K</sup>, TF-1 pLVX (IDH2<sup>R140Q</sup>), TF-1 pLVX (IDH2<sup>R172K</sup>), U87MG pLVX (IDH2<sup>R172K</sup>), U87MG pLVX (IDH2<sup>R140Q</sup>) cell lines with IC<sub>50</sub> values of 0.53, 0.02, 0.98, 1.59, and 0.01  $\mu$  M, respectively. In the presence of 0.1  $\mu$  M Enasidenib, IDH2<sup>R140Q</sup> cells exhibited an approximately 50% decrease in intracellular 2HG and an increase in the percentage of cells expressing cell surface markers associated with granulocytic differentiation. Incubation of IDH2<sup>R140Q</sup> blast cells with 5  $\mu$  M Enasidenib for 8 days significantly increased the number of cells with multilobed nuclei when compared with control cells. In tumor-bearing mice, two doses of 25 mg/kg enasidenib given 12h apart resulted in 99.2% inhibition of 2HG production in tumors. In a mouse xenograft model of primary human AML, administration of enasidenib (30 mg/kg, twice daily) for 38 days reduced serum and intracellular 2HG levels compared to vehicle-treated group<sup>[2]</sup>.

**储存****储存条件:**

粉末	-20°C	3年
液体	-80°C	1年

**运输条件:**

Shipped in cold pack